Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3-4
|
| pubmed:dateCreated |
1996-10-1
|
| pubmed:abstractText |
CD3 engagement has been used as a surrogate for antigen-specific stimulation to trigger T cell effector functions. Exogenous IL-2 has been used to prolong and amplify CD3-induced T cell activation. Previous studies have been shown that CD3 reactivity is increased in cancer patients with preactivated (> 10% HLA-DR+) T cells in the peripheral blood. In this study, we report 9 courses of a single infusion of anti-CD3 mAb (OKT3) followed by continuous infusion of intermediate dose IL-2 in 4 cancer patients [2 multiple myeloma (MM), 1 B-cell lymphoma (NHL), 1 metastatic melanoma (ME)] with advanced disease and > 10% HLA-DR+ T cells in the peripheral blood. An increase of lymphocytes, equally distributed between CD4+ and CD8+ subsets, was observed during treatment. Activation was phenotypically documented by the emergence of CD25+ cells in the peripheral blood. Unexpectedly, functional studies [including proliferation to mitogens (PHA, OKT3) and cytotoxicity assays (NK and LAK activities)] did not parallel phenotypic data and a slight decrease of all functions was observed after OKT3 and IL-2 treatment. OKT3 and IL-2 infusions were well tolerated and no limiting toxicity was observed. The treatment did not revert tumor progression in the 2 patients with progressive disease (NHL, ME) and had only minimal effects in the 2 MM patients with stable disease. These data indicate that the sequential administration of OKT3 and IL-2 had no anti-tumor activity in this small series of patients with advanced cancer who were selected for treatment because of an increased number of HLA-DR+ T cells in the peripheral blood. A discrepancy was observed between the emergence of CD25+ T cells and the clinical outcome.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
1042-8194
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
21
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
325-30
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:8726415-Antibodies, Monoclonal,
pubmed-meshheading:8726415-Antigens, CD3,
pubmed-meshheading:8726415-CD4-CD8 Ratio,
pubmed-meshheading:8726415-Drug Administration Schedule,
pubmed-meshheading:8726415-Female,
pubmed-meshheading:8726415-HLA-DR Antigens,
pubmed-meshheading:8726415-Humans,
pubmed-meshheading:8726415-Immunotherapy,
pubmed-meshheading:8726415-Infusions, Intravenous,
pubmed-meshheading:8726415-Interleukin-2,
pubmed-meshheading:8726415-Leukocyte Count,
pubmed-meshheading:8726415-Lymphocyte Activation,
pubmed-meshheading:8726415-Lymphoma, B-Cell,
pubmed-meshheading:8726415-Male,
pubmed-meshheading:8726415-Melanoma,
pubmed-meshheading:8726415-Middle Aged,
pubmed-meshheading:8726415-Multiple Myeloma,
pubmed-meshheading:8726415-Phenotype,
pubmed-meshheading:8726415-Platelet Count,
pubmed-meshheading:8726415-T-Lymphocytes,
pubmed-meshheading:8726415-Treatment Outcome
|
| pubmed:year |
1996
|
| pubmed:articleTitle |
Clinical and immunological studies in advanced cancer patients sequentially treated with anti CD3 monoclonal antibody (OKT3) and interleukin-2.
|
| pubmed:affiliation |
Università di Torino, Dipartimento di Medicine e Oncologia Sperimentale, Ospedale Molinette, Torino, Italy.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|